Skip to content

Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity

Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03232255
Enrollment
30
Registered
2017-07-27
Start date
2017-08-25
Completion date
2017-12-07
Last updated
2018-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dentin Sensitivity

Brief summary

This study is to evaluate the benefit and tolerability of a Mouthrinse (IQP-OLP-101) in the treatment of dentine hypersensitivity.

Interventions

OTHERMouthrinse (IQP-OLP-101)

Rinse/gargle 10mL of Mouthrinse for 60 seconds after tooth brushing, twice a day.

Sponsors

InQpharm Group
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. At least one hypersensitive tooth in everyday life after PAV 1 in-office visit 2. At least one hypersensitive tooth in everyday life with a regular pain perception of at least 2 times per week after PAV 1 visit 3. At least one tooth with dentine hypersensitivity to air stimulation → VAS ≥ 40mm at study entry 4. Any sensitive tooth showing exposure of cervical dentine (gum recession) and no acute signs of caries on the exposed root 5. For subjects entering the study at stage PAR-control: good healing of the periodontal surgery site, cause of pain must not be the result of the periodontal surgery 6. Age ≥ 18 years and ≤ 75 years 7. Willing and able to attend the on-study visits 8. Willing and able to understand and to follow the study procedures and instructions 9. Good oral hygiene throughout the study 10. Written informed consent before participation in the study 11. Subjects have undergone dental hygiene treatment immediately prior to study inclusion (except subjects entering the study at stage PAR-control)

Exclusion criteria

1. Hypersensitivity only due to sweets 2. Allergic reactions to any ingredients of InQpharm Mouthrinse e.g. chlorhexidine, zinc lactate 3. Professional desensitizing therapy during the previous 3 months; GLUMA (glutaraldehyde/hydroxyethyl methacrylate) desensitizer application within 6 months 4. Chronic systemic anti-inflammatory and analgesic medications 5. Systemic disorders causing or predisposing to dental (e.g. dry mouth, reflux, eating disorders, etc.) 6. Teeth or supporting structures with any other painful pathology or defect 7. Subject with poor health conditions 8. Concurrent participation in another clinical trial 9. Pregnant or lactating women

Design outcomes

Primary

MeasureTime frameDescription
Change in dentine hypersensitivity28 daysAssessed by subjects using VAS

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026